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Abstract 
 Nicotinamide adenine dinucleotide, NAD, is an essential redox factor in many, 
primarily catabolic, hydrogen transfer reactions. While the redox reactions are not 
accompanied by a net loss of the pyridine nucleotides, NAD+ is actively degraded in a variety 
of ADP-ribosyl transfer reactions which are implicated, for examples, in cellular stress 
responses, calcium signalling and genomic stability. Thus, a continuous biosynthesis of NAD 
is essential for cell viability and metabolism. The final step in NAD biosynthesis, the 
reversible transfer of the AMP moiety from ATP onto a pyridine mononucleotide (NMN or its 
acidic form) is catalysed by nicotinamide mononucleotide adenylyltransferases (NMNATs) 
and is common to both the de novo and the known salvage pathways. In humans, three 
NMNAT isoforms have been described and partially characterised. The present study was 
aimed at a comprehensive characterisation of the human NMNATs, in particular, with regard 
to isoform-specific functions in order to gain further insight into the cellular NAD 
homeostasis and its regulation. 
Kinetic studies revealed that NMNAT1 possesses the highest specific activity both in the 
forward and reverse reactions, while NMNAT3 exhibited the lowest substrate selectivity. 
Importantly, NMNAT3 readily used the reduced nicotinamide substrates (NMNH or NADH 
in the forward and reverse reaction, respectively) thereby indicating that besides NAD+, 
NADH may be directly formed from a reduced precursor. No significant inhibition by 
physiological intermediates including nucleotides and nucleosides as well as poly(ADP-
ribose), PAR, was found. However, we observed a considerable activation, particularly of 
NMNAT2, by the green tea polyphenol epigallocatechin 3-gallate (EGCG). 
Investigations of the subcellular distribution established distinct localisations of the three 
NMNAT isoforms in the nucleus, the Golgi complex and the mitochondria. Structural 
analyses revealed that all human NMNATs have insertions in their primary structures which 
are absent from the bacterial counterparts. While in NMNAT1 this region of the protein 
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contains a known nuclear localisation signal, we revealed a targeting function of a 
corresponding domain in NMNAT2. The stretch of amino acids 109-192 was shown to direct 
the protein to the Golgi complex. Deletion of this domain resulted in a catalytically active, 
cytosolic protein. Moreover, we demonstrated that cysteine palmitoylation within this 
targeting domain is essential to anchor NMNAT2 at the cytosolic surface of the Golgi 
complex. The isoform NMNAT1 is known to be targeted to the nucleus by a nuclear 
localisation signal, which we highlight to reside within the corresponding domain. An 
important additional function of this targeting domain in NMNAT1 was also established. We 
found that this region (amino acids 102-149) mediates a phosphorylation-dependent 
association with poly(ADP-ribosyl)ated PARP1 which substantially enhances the poly(ADP-
ribosyl)ating activity of PARP1. Interestingly, the catalytic activation of PARP1 was 
independent of the ability of NMNAT1 to synthesise NAD, as revealed using a catalytically 
dead mutant of NMNAT1. 
Collectively, our results suggest that the inserts into the sequences of the human NMNATs 
mediate subcellular targeting and interactions with other cellular factors. Therefore, we 
propose to denote this region as isoform-specific targeting and interaction domain (ISTID). It 
will be important to establish this function also for the corresponding domain in the 
mitochondrial isoform, NMNAT3. Interestingly, its amino acid sequence indeed lacks a 
classical N-terminal targeting sequence implying another mode of mitochondrial import. 
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1. INTRODUCTION 
1.1 Metabolism, pools, and signalling functions of the redox cofactor nicotinamide adenine 
dinucleotide 
 NAD collectively stands for nicotinamide adenine dinucleotide in its oxidised, NAD+, 
and reduced form, NADH (Fig.1). NAD is a well known cofactor in mostly catabolic 
reduction/oxidation (redox) reactions in for example glycolysis, citric acid cycle and oxidative 
phosphorylation. Phosphorylation of NAD+ by NAD kinase yields NADP (Fig.1). The redox 
couple NADP+/NADPH serves mainly in reductive hydrogen transfer reactions catalysed by 
for example glucose 6-phosphate dehydrogenase in the pentose phosphate pathway. In 
general, the ratios of NAD+/NADH and NADP+/NADPH reflect the redox state of a cell 
(Pollak et al., 2007). Under physiological conditions, cellular NAD levels exceed those of 
NADP. Furthermore, NAD is mostly present in its oxidised form with a ratio of 
NAD+/NADH ~ 3-10 (Zhang et al., 2002; Ido Y, 2007). The concentration of total cellular 
NAD is estimated to be in the submillimolar range (Pollak et al., 2007), and the majority of 
the nucleotide is suspected to be protein-bound (Williamson et al., 1967). The intracellular 
pool of NAD is commonly subdivided into the mitochondrial and the nucleo-cytosolic pool. 
This is because under normal cellular conditions, the inner mitochondrial membrane is 
assumed to be impermeable for NAD and NADP (DiLisa&Ziegler, 2001), whereas the 
nucleotides most likely freely diffuse through the pores of the nuclear envelope (Zhang et al., 
2002). In contrast to yeast (Todisco et al., 2006), mitochondrial NAD transporters have not 
been found in mammals. 
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 Figure 1: Electron transfer reactions of NAD(P). The NAD+/NADH redox couple exerts a 
vital function as cofactor of dehydrogenases in several metabolic redox reactions. NAD+ can 
be phosphorylated at the 2’-hydroxyl group of the adenosine ribose by NAD kinase. The 
product of this reaction, NADP+, also serves as electron acceptor in redox reactions. 
 2 
Redox equivalents are exchanged between cytosol and mitochondria by dehydrogenase 
dependent NADH shuttles (McKenna et al., 2006) and the activity of mitochondrial 
nicotinamide nucleotide transhydrogenase (NNT) (Jackson JB, 2003). Reduced nucleotides 
could have a particular impact on mitochondrial NAD metabolism. In mitochondria, the ratio 
of free NAD+/NADH is only ~7-8, while the level of free cytosolic NADH is ~700 times 
lower than that of NAD+ (Williamson et al., 1967; Zhang et al., 2002). Although, the 
mitochondrial NAD pool is considered to contain significant amounts of the total cellular 
NAD, uncertainty exists about how it is established (Pollak et al., 2007). In 1996, Barile et al. 
reported an ATP dependent NAD synthesising activity in rat liver mitochondria (Barile et al., 
1996). Apart from this, no other NAD biosynthetic activity could clearly be associated with 
the mitochondria. 
 The utilisation of NAD in energy metabolism as essential electron carrier does not 
result in a net consumption of the nucleotide. The need for continuous NAD synthesis has 
only been recognised following the recent discoveries of a variety of NAD catabolising 
processes (Berger et al., 2004). Commonly, pyridine nucleotides degrading reactions include 
the transfer of ADP-ribose from NAD+ or NADP+ onto an acceptor molecule under release of 
nicotinamide (Fig.2) which, in turn, regulates most of these reactions in a negative feedback 
fashion (Pollak et al., 2007). ADP-ribose transfer reactions and their products are involved in 
the regulation of calcium signalling, genome stability, ageing/longevity, oxidative stress 
response and cell death (Virág L., 2005; Belenky et al., 2007; Beneke&Bürkle, 2007; Dali-
Youcef et al., 2007; Fliegert et al., 2007; Pollak et al., 2007; Ying W., 2008). Thus, the 
absolute amounts of NAD and NADP, and not only their redox ratios, are crucial for the 
maintenance of cellular viability. NADP+ serves as substrate of the multifunctional enzyme 
CD38 to generate NAADP, the most potent calcium releasing compound in the cell (Lee 
H.C., 2000; Yamasaki et al., 2005). Apart from this, most of the transfer reactions strictly 
depend on NAD+ as substrate. For example, the classes of ADP-ribose transferases (ARTs) 
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and poly(ADP-ribose) polymerases (PARPs) transfer either a single ADP-ribose molecule or 
up to 200 units, respectively, from NAD+ onto acceptor proteins (Hassa et al., 2006; Koch-
Nolte et al., 2008) (Fig.2). 
 
 
 
Figure 2: NAD consumption. NAD+ serves as substrate for ADP-ribose transfer reactions 
like mono and poly(ADP-ribosyl)ation of acceptor molecules which are catalysed by ADP-
ribosyl transferases (ARTs) and poly(ADP-ribose) polymerases (PARPs) under release of 
nicotinamide (Nam). 
 
Both, ADP-ribose and poly(ADP-ribose) (PAR) can be cleaved off the acceptor by specific 
hydrolases, ADP-ribose-protein hydrolases and PAR glycohydrolase (PARG). The liberated 
PAR has been reported to directly mediate apoptotic cell death, although the exact mechanism 
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is not yet understood completely (Yu et al., 2006; Andrabi et al., 2006; Li et al., 2007). In 
fact, all free NAD derivatives are proposed to exhibit signalling functions. For example, the 
metabolite of NAD+-dependent protein deacetylation, O-acetyl ADP-ribose (OAADPR), 
influences calcium homeostasis through its binding to TRPM2 calcium channels (Grubisha et 
al., 2006). The comprehensive role of NAD in cellular signalling is possible due to the 
localisation of the respective enzymatic activities to subcellular compartments like 
mitochondria, nucleus, cytosol and the extracellular space. Therefore, gaining insight into to 
the mechanism and distribution of NAD biosynthesis should be of utmost concern. 
 
1.2 NAD biosynthesis 
 NAD biosynthesis proceeds via several different routes and has been extensively 
studied (Magni et al., 2008). In general, the de novo synthesis can be distinguished from the 
recycling salvage pathway (Fig.3). De novo NAD synthesis in eukaryotes utilises the essential 
amino acid L-tryptophan as precursor and proceeds via quinolinic acid with the generation of 
nicotinic acid mononucleotide (NaMN), one of two possible mononucleotide intermediates. 
Precursors of the salvage pathway are nicotinic acid (NA), nicotinamide (Nam) and 
nicotinamide riboside (NR) which are either recycled by pyridine nucleoside and nucleotide 
hydrolases activities and ADP-ribosylation reactions (Noctor et al., 2006; Magni et al., 2008) 
or taken up from food sources. The deficiency of NA and Nam (together niacin) causes severe 
degenerative symptoms which eventually classified them as Vitamin B3 (Elvehjem C.A., 
1939). As substrates for nicotinic acid phosphoribosyltransferase (NAPRT) and nicotinamide 
phosphoribosyltransferase (NamPT), they are metabolised to their mononucleotide 
equivalents, NaMN and nicotinamide mononucleotide (NMN), respectively, by the transfer of 
the phosphoribose moiety of phosphoribosyl pyrophosphate (PRPP) onto the pyridine ring 
(Fig.3). 
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Figure 3: NAD biosynthesis in humans. Human NAD biosynthesis is established by de novo 
synthesis from the amino acid tryptophan and three salvage pathways. In the de novo 
synthesis, quinolinic acid phosphoribosyltransferase (QPRT) catalyses the transfer of the 
phosphoribose moiety from PRPP onto quinolinic acid. The product of this reaction is NaMN. 
In the salvage pathway, NAPRT and NamPT synthesise NaMN and NMN (nicotinamide 
mononucleotide), from nicotinic acid and nicotinamide, respectively. Nicotinamidase activity 
has not been identified in vertebrates, yet. It is present in lower organisms which lack NamPT. 
Nicotinamide riboside (NR) kinases, NRK1 and 2, phosphorylate NR to generate NMN. All 
routes eventually merge at the ATP-dependent step of dinucleotide generation by NMNAT 
activity. NAAD (Nicotinic acid adenine dinucleotide) is amidated to NAD+ by NAD synthase 
(NADS). 
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In contrast to eukaryotes, bacteria do not express NamPT and are, therefore, not capable to 
directly synthesise NMN from Nam and PRPP. The conversion of Nam to NA by a 
nicotinamidase activity, however, allows for the utilisation of Nam in bacterial and plant 
NAD synthesis (Rongvaux et al., 2003; Wang&Picherski, 2007). This activity has not been 
identified in mammals. An alternative pathway, the phosphorylation of NR to NMN, has 
recently regained interest due to the identification of two human nicotinamide riboside 
kinases (NRK1 and NRK2) in humans (Bieganowski&Brenner, 2004). NR has been found as 
nutrient in milk which suggests a vitamin character for the nucleoside, similar to niacin. 
Common to all pathways is the final generation of respective pyridine adenine dinucleotides 
by the reversible transfer of AMP onto NMN or NaMN (Fig.3). This essential step in NAD 
biosynthesis is catalysed by nicotinamide mononucleotide adenylyltransferases (NMNATs). 
 
1.3 The family of nicotinamide mononucleotide adenylyltransferases 
 NAD synthesis by NMNATs has been extensively studied since the 1970ies (Magni et 
al., 1999; Magni et al., 2004; Lau et al., In press). However, the first NMNAT activity was 
already described 20 years before by Sir Arthur Kornberg in his reports on the reverse 
reaction of NAD synthesis, namely the pyrophosphorylysis of NAD and NADH 
(Kornberg&Lindberg, 1948; Kornberg A., 1950) (Fig.4). NMNATs are globular proteins of 
20 to 50 kDa and mostly assemble into homo-oligomers of two to six subunits. The overall 
tertiary fold of NMNATs is highly conserved and resembles the dinucleotide binding fold of 
α/β phosphodiesterases which is established by two structurally related βαβαβ 
mononucleotide binding Rossmann folds (Rossmann et al., 1975; Raffaelli et al., 1997). The 
NMNAT-specific catalytic and substrate binding motif GxFxPx[H/T]xxH can be found at the 
N-terminus of the enzymes. A second, C-terminal motif, ISSTxxR, is implicated in substrate 
binding (Emanuelli et al., JBC2001; Saridakis&Pai, JBC2003) (Fig.5). 
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Figure 4: The NMNAT reaction. The reversible adenylyltransfer catalysed by NMNATs 
utilises ATP for the generation of either nicotinamide adenine dinucleotide (NAD) or its 
deamidated form nicotinic acid adenine dinucleotide (NAAD) from the respective 
mononucleotides (NMN or NAMN) and under release of inorganic pyrophosphate (PPi). 
 
Substrate specificities of NMNATs with respect to NMN or NaMN are particularly mediated 
by structural water molecules (Lau et al., In Press). Prokaryotic NMNATs display strong 
preference towards either NaMN or NMN, whereas human NMNATs are capable of utilising 
both nucleotides in vitro (Magni et al., 2004; Lau et al., In press). In an alternative pathway, 
reduced NMN, NMNH, has been suggested to serve as substrate for NMNATs 
(Kornberg&Pricer, 1951). Moreover, NMNH may serve as cofactor for certain redox 
reactions (Fischer&McGregor, 1969). It remains to be established whether NADH could 
indeed be synthesised directly, for example via the NRK/NMNAT route. 
 Intriguingly, overexpression of NMNAT results neither in elevated NAD levels nor in 
a change of the redox state in mammalian cells (Anderson et al., 2002). In contrast, it 
stimulates NAD dependent processes like nuclear histone deacetylation which indicates 
increased NAD turnover (Sasaki et al., 2006). These observations suggest that NAD 
biosynthesis may specifically fuel NAD-dependent signalling processes rather than affect 
cellular NAD homeostasis. 
 8 
 Figure 5: Multiple sequence alignment of NMNATs. The multiple sequence alignment of 
selected NMNAT homologues was generated using Muscle (Edgar R.C., 2004). Regions 
which fold as β-sheets in known crystal structures are coloured in yellow. Increasing 
significance of the Blossum 62 matrix scores in the alignment is reflected by successively 
darkening blue. Lau et al., In press 
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1.4 Three NMNAT isoforms in humans 
 In humans, three NMNAT gene products are known to date. Despite their relative high 
sequence identity, the isoforms display a number of differences (Tab.1). For example, the 
major activity, NMNAT1, locates to the nucleus (Schweiger et al., 2001), whereas the exact 
localisation of NMNAT2 and 3 has not been as definite. NMNAT2 was found to locate to 
cytosol and nucleus (Zhang et al., 2003; Yalowitz et al., 2004). NMNAT3 has been detected 
in the cytosol and possibly mitochondria (Zhang et al., 2003). This means this isoform could 
contribute to the mitochondrial NAD pool (1.1). The primary structures of human NMNATs 
differ from that of their prokaryotic homologues particularly by a variable insertion upstream 
of β-sheet 4 (Fig.5). Its implication in catalysis might be questionable due to its lack in 
bacterial NMNATs. Interestingly, human NMNAT1 harbours its nuclear localisation signal 
here (Schweiger et al., 2001). Yeast NMNATs have also been proposed to locate to the 
nucleus (Emanuelli et al., 1999; Emanuelli et al., 2003). Yet, the targeting of these enzymes 
and, therefore, a possible implication of this insertion has not been studied. Interestingly, 
NMNAT2 and 3 are tissue-specific, while nuclear NMNAT1 is considered to be ubiquitously 
expressed (Emanuelli et al. 2001; Raffaelli et al., 2002; Zhang et al., 2003; Yalowitz et al., 
2004) (Tab.1). It appears important to reveal whether the three human NMNAT isoforms 
exhibit redundant or isoform-specific functions in the living cell. 
 Tumour cells are known to exhibit lower NMNAT activity than normal cells 
(Branster&Morton, 1956; Emanuelli et al., 2001), which prompted the search for substrate 
analogues as exogenous inhibitors (Franchetti et al., 2005; Sorci et al., 2007). Despite recently 
established isoform-specific substrate and product inhibition (Sorci et al., 2007) (Tab.1), all 
tested inhibitors failed to efficiently affect any NMNAT activity. That several pyridine or 
purine nucleotide derivatives might indeed serve as alternative substrates has been reported 
for the yeast homologues (Magni et al., 2004), but has not been investigated in case of the 
human NMNATs. In addition, sufficient information on isoform-specific catalytic 
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mechanisms in humans was lacking until recently (Sorci et al., 2007), and this study. 
Substrate accommodation and catalytic efficiency are influenced by the capability to provide 
hydrogen bonds (Zhang H. et al., 2002) but also by the enzymes quaternary structure 
(D’Angelo et al., 2000; Werner et al., 2002; Zhou et al., 2002). Indeed, human NMNAT 
isoforms exhibit different quaternary structures (Tab.1) (Lau et al., In press). NMNAT1, for 
example, assembles into a homo-hexamer, which may account for a more efficient catalysis. 
 
Table 1: Three human NMNAT isoforms. 
 NMNAT1 NMNAT2 NMNAT3 
Ensembl: ENSG00000 173614 157064 163864 
Chromosome 1p36.2(1) 1q25(8,9) 3q23(11) 1  
High 
Skeletal muscle,  
heart,  
liver, kidney(5)
Brain(8,10)
Lung,  
spleen(7)Tissue  
mRNA levels 
Low 
Brain(1)
cancer cells(5)
Heart, muscle(10)
Placenta, kidney, 
cancer cells(7)
CDS (bp) 840 924 756 
Theoretical molecular mass 2 (Dalton) 31 932 34 439 28 322 
UniProtKB accession number Q9HAN9 Q9BZQ4-1 Q96T66-1 
Tertiary structure  
Hexamer(2-4) 
tetramer(5)
Monomer 
(8)
Tetramer 
(7)
Substrate specificity(6) NMN NMN/NaMN NMN/NaMN 
Competitive 
NAD, NaAD 
vs. ATP 
NAD, NaAD 
vs. ATP 
NAD, NaAD 
vs. NMN Product 
inhibition(6)
Non-competitive 
PPi vs.  
NMN and ATP 
None None 
NMNAT2 36; 37(7)   Protein sequence  
 
identity 3 % NMNAT3 49; 50(7)  39; 34(7)
 
(1) The corresponding annotated gene product, Q96T66-2, lacks the essential NMNAT-specific ATP binding 
motif at its N-terminus, and has, so far, not been subject of experimental investigations. Splice variant 1, 
Q96T66-1, is alternatively annotated in the RefSeq database as gene product FKSG76 (AAK52726) encoded on 
chromosome 8. (2) ExPASy server tool Compute pI/Mw, average resolution mode (3) extracted from ClustalW 
(V1.83) pairwise alignment 
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1.5 Nuclear poly(ADP-ribosyl)ation by PARP1, and cell viability 
 The catalytic activity of poly(ADP-ribose) polymerases, PARPs, modifies acceptor 
molecules with ADP-ribose moieties from NAD+ and eventually generates protein-bound, 
branched poly(ADP-ribose) (PAR) chains (Bürkle et al., 2005) (Fig.2). PAR-sylation is a 
post-translational modification that is involved in a variety of physiological and 
pathophysiological events (Schreiber et al., 2006; Hassa&Hottiger, 2008). The major cellular 
PARP activity is represented by the nuclear localised PARP1 which, under physiological 
conditions, detects DNA strand breaks and recruits DNA repair proteins, thereby regulating 
e.g. genome maintenance and ageing (Dantzer et al., 2000; Oei et al., 2005; Kim et al., 2005; 
Bürkle A., 2006) (Fig.6). Besides the modification of target proteins like p53 and histone H1, 
PARP1 serves as major acceptor itself (Adamietz P., 1987; Mendoza-Alvarez&Alvarez-
Gonzalez, 2001; Kun et al., 2002).  
 
 
 
Figure 6: Cellular effects of PAR and PARP1 function. 
PARP1 and the generation of nuclear poly(ADP-ribose) 
(PAR) is activated by DNA strand breaks, which causes 
PARP1 automodification under NAD+ utilisation and 
nicotinamide (here: NAm) release. The subsequent cellular 
effects are diverse and play crucial roles in the regulation of 
several physiological and pathophysiological processes, e.g. 
ageing. PARP and PAR related effects are regulated by, 
amongst others, substrate (NAD+) supply, nicotinamide 
feedback inhibition and the degree of PARP1 
automodification. Kim et al., 2005 
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Pathophysiologic events such as ischaemia-reperfusion or inflammation result in the release 
of reactive oxygen species (ROS) which causes extensive DNA damage (Virág L., 2005) 
(Fig.7). As a response, PARP1 activity rises to more than 100-fold which eventually leads to 
depletion of cellular NAD+ pools, energy depletion and necrotic cell death (Juarez-Salinas et 
al., 1979; Shie et al., 1998; Meli et al., 2003). Further, PARP1 hyperactivation induces 
apoptotic cell death by mediating translocation of apoptosis inducing factor (AIF) from the 
mitochondria to the nucleus (Yu et al., 2002). In fact, PAR directly triggers AIF translocation 
in a dose dependent manner (Yu et al., 2006; Li et al., 2007) and has been identified as cell 
death signal in neuronal excitotoxicity (Andrabi et al., 2006). The second product of 
poly(ADP-ribosyl)ation, Nam, inhibits nuclear NAD+-dependent histone deacetylation by 
SIRT1. SIRT1 is the founding member of sirtuins, the mammalian counterpart of yeast Sir2, 
and regulates gene expression and cell stress response (Dali-Youcef et al., 2007). Elevated 
NAD biosynthesis by overexpression of nuclear NMNAT1 has been shown to delay 
neurodegeneration, supposedly by the mediation of SIRT1 function (Wang et al., 2005; Araki 
et al., 2004). Also, an impact of NMNAT1 on PARP1 activity has been suggested, but 
remains to be demonstrated (Schweiger et al., 2001; Uhr&Smulson, 1982; Bouchard et al., 
2003). In line with such interplay between NAD metabolic events, it would be interesting to 
know whether the products of PARP1 and SIRT1, PAR, Nam and OAADPR may, in turn, 
exert regulatory effects on NMNAT activity. 
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Figure 7: Cell death cycle via nuclear poly(ADP-ribosyl)ation. Hyperactivation of nuclear 
PARP1 (and 2) by excessive DNA damage can experimentally be induced by, e.g. alkylating 
agents like MNNG, but also by reactive oxygen species (ROS) including hydrogen peroxide. 
As a result, the cellular pool of NAD, which serves as substrate for the poly(ADP-
ribosyl)ation reaction, becomes depleted, and cell death pathways are initiated, e.g. via 
nuclear translocation of apoptosis inducing factor (AIF) or energy depletion. These processes 
also play a crucial role in pathophysiological states such as inflammation and ischaemia-
reperfusion damage. Beneke & Bürkle, 2007 
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2. AIMS OF STUDY 
 Efficient biosynthesis of nicotinamide adenine dinucleotide (NAD) is vital to all 
organisms. It supplies a variety of NAD(P) dependent and degrading signalling processes 
which are involved in, amongst others, cellular stress response, genomic stability, calcium 
signalling and viability (Pollak et al., 2007; Ying W., 2008). The final step in the generation 
of the dinucleotide is catalysed by nicotinamide mononucleotide adenylyltransferases 
(NMNATs). This essential enzymatic activity has been studied since 1950, and was initially 
thought to fuel a general cellular NAD pool. However, the recent identification of three 
human NMNAT isoforms with differential tissue expression profiles appears to challenge this 
view. In order to establish the possibility of non-redundant functions of the human NMNATs, 
we aimed to examine their sub-cellular localisation and catalytic properties, also with regard 
to regulation by NAD metabolites. NMNAT1 is known to reside in the cell nucleus. 
Therefore, we wanted to elucidate an earlier proposed functional relationship to the cells 
major NAD+-degrading activity owned by the nuclear enzyme poly(ADP-ribose) polymerase 
1 (PARP1). To further examine the proposed extra-nuclear distribution of NMNAT2 and 3 
promised to reveal information about the establishment of extra-nuclear NAD pools and was, 
therefore, part of this study. NMNAT1 harbours its localisation signal within an apparently 
inserted loop region within the conserved dinucleotide binding fold. Intriguingly, all human 
NMNATs can be distinguished from their bacterial homologues by this feature. Its high 
flexibility and structurally external residence encouraged us to establish whether and how it 
could allow for mediating post-translational modification, sub-cellular localisation or 
intermolecular interactions of human NMNATs. 
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3. SUMMARY OF RESULTS 
 The biochemical characterisation of three human NMN adenylyltransferases 
(NMNATs), in the study of paper I, could corroborate that the isoforms exert non-redundant 
activities through differential catalytic properties and sub-cellular distribution. In addition to 
the nuclear localisation of human NMNAT1, we established the distribution of isoform 2 and 
3 to the Golgi complex and mitochondria, respectively. In addition to the distinct sub-cellular 
compartmentation, the human NMNAT isoforms also displayed differential catalytic 
properties. NMNAT1 is assumed to be ubiquitously expressed and proved to exhibit the 
highest specific activity in catalysing both the forward and reverse reaction of the reversible 
NAD synthesis, NMN + ATP NAD + PPi (Fig.4). We could further reveal restricted 
substrate specificity for this isoform. In contrast, NMNAT3 accepts a variety of substrate 
analogues. Strikingly, the reduced nicotinamide mononucleotide, NMNH, proved to serve as 
even better substrate than NMN. The discovery that also NMNAT1 and 2 can synthesise 
NADH from NMNH establishes a pathway to generate the reduced dinucleotide directly. In 
contrast to the apparent lack of exogenous inhibitors of NMNAT activity, we revealed the 
green tea polyphenol (-)-epigallocatechin 3-gallate (EGCG) to be capable of activating NAD 
synthesis catalysed by NMNAT2 and 3. However, nucleotide intermediates of the NAD 
metabolism failed to efficiently affect the activity of any NMNAT isoform. We could also 
demonstrate that all isoforms appear to co-exist at least in some cell types. Therefore, it 
remains to be elucidated whether and how this triplicate NAD synthesis by human NMNATs 
is endogenously regulated besides its tissue-specific occurrence and possibly in concert with 
its sub-cellular compartmentation. 
 The distribution of human NMNAT2 to the Golgi complex is not only puzzling with 
respect to the physiological importance of NAD synthesis at this compartment but also due to 
the lack of an N-terminal targeting sequence. In paper II, we could demonstrate that an 
isoform-specific variable domain, which is largest in case of NMNAT2 (Lys107-Leu192) and 
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absent in bacteria (Fig.5), facilitates the post-translational lipid anchoring of NMNAT2 at cis-
Golgi membranes. Moreover, two adjacent cysteine residues (Cys164 and Cys165) within this 
domain could be identified as target site for the palmitoylation, which is crucial for the 
enzyme’s Golgi localisation. This indicates that NMNAT2 activity is most likely facing the 
cytosol. Importantly, the deletion of amino acids Val109 to Leu192 did not affect the catalytic 
activity of NMNAT2. Together, these findings suggest that this isoform-specific domain 
carries regulatory rather than catalytic functions. 
 In paper III, we demonstrate that the phosphorylation state of NMNAT1 regulates the 
activation of poly(ADP-ribosyl)ated PARP1. We could also prove a regulatory role of the 
newly identified isoform-specific domain in human NMNAT1 by our discovery that a PKC-
specific phosphorylation site resides here (amino acid Ser136 within Gln107 - Pro149, Fig.5). 
NMNAT is a homo-hexamer and, therefore, possesses six potential phosphorylation sites per 
assembled enzyme. Despite the close proximity to the enzyme’s nuclear localisation signal, 
we could not observe an effect of phosphorylation on sub-cellular targeting. However, a 
negative charge at Ser136 diminished a physical interaction of this NAD biosynthetic enzyme 
with the major cellular NAD degrading activity, PARP1 via PAR, and, thereby, PARP1 
stimulation in presence of NMNAT1. We further demonstrated that a physical interaction of 
NMNAT1 with PAR is essential for accelerating PARP1 activity. An additional substrate 
channelling effect could be important in vivo. A putative PAR binding motif for NMNAT1 
could be predicted to reside close to Ser136 in the proteins tertiary structure. It remains to be 
elucidated, whether PAR binding and PARP1 activation is gradually regulated by successive 
phosphorylation of the homo-hexameric NMNAT1. Furthermore, we provide evidence that 
the functional interplay between NMNAT1 and PARP1 activity is of pathophysiological 
relevance. In cells overexpressing NMNAT1, in response to oxidative stress induced DNA 
damage, we observed an accelerated nuclear translocation of apoptosis inducing factor, which 
is a hallmark of PAR mediated cell death. 
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Figure 8: Summary of results Human NMNATs are localised to three distinct sub-cellular 
compartments, nucleus (NMNAT1), cis-Golgi complex (NMNAT2), and mitochondria 
(NMNAT3). The targeting is at least in case of NMNAT1 and 2 mediated by an isoform-
specific loop domain which is dispensable for enzymatic function. NMNAT2 is membrane 
anchored by cysteine palmitoylation within this domain. The loop domain of NMNAT1 
harbours a PKC specific phosphorylation site. Phosphorylation diminishes the interaction 
with and the stimulation of automodified PARP1, which would otherwise induce AIF release 
from the mitochondria. The activity of NMNAT3 and especially NMNAT2 is enhanced by 
EGCG. In vitro, NMNAT3 preferably catalyse the reversible synthesis of NADH. We propose 
non-redundant functions of the three human NMNAT isoforms. (ER, endoplasmic reticulum. 
PM, plasma membrane) 
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4. DISCUSSION 
4.1 Non-redundant functions of human NMNATs and possible individual impact on cell 
viability 
 Human NMNATs are not only tissue-specifically expressed but also distributed to 
distinct sub-cellular compartments, the nucleus (NMNAT1), the Golgi complex (NMNAT2) 
and the mitochondria (NMNAT3), as we could establish with paper I. The compartment-
specific occurrence of human NMNATs might very well reflect non-redundant, tissue- but 
also cell-type specific functions. Evidence which supports this assumption is also provided by 
the fact that NMNAT2 expression was detected in pancreatic beta cells but not in pancreatic 
acinar cells (Yalowitz et al., 2004). Thus, it is tempting to propose that the NMNAT 
expression profile and their sub-cellular distribution determine a cell’s response to metabolic 
changes and oxidative stress by directing the output of cellular NAD synthesis to particular 
response mechanisms. This could also partially account for cell type-specific phenomena such 
as metabolic dysfunction and ageing (Ramsey et al., 2008). 
 It has to be noted that the NMNAT catalysed step in NAD biosynthesis is not rate 
limiting (Magni et al., 2008), which indicates that NAD homeostasis is regulated beyond 
NMNAT activity. A general impact of NMNAT1 on NAD homeostasis has indeed been 
questioned since overexpression of the nuclear NAD biosynthetic enzyme fails to increase 
cellular NAD levels (Anderson et al., 2002). Its activity, however, stimulates NAD turnover 
by nuclear SIRT1 and has been proposed to mediate neuroprotection via SIRT1 regulated 
gene expression (Araki et al., 2004). NAD+-dependent deacetylases are also found in 
mitochondria. For example, SIRT4 controls cellular insulin secretion by deacetylation of 
glutamate dehydrogenase (Haigis et al., 2006). It would be interesting to test whether 
NMNAT3 supports this process. We could demonstrate in paper I and II that NMNAT2 
locates to the Golgi complex. This compartment is known to harbour two poly(ADP-ribose) 
polymerases, tankyrase 1 and 2, which are involved in glucose homeostasis (Yeh et al., 2007), 
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telomere function and ageing (Hsiao&Smith, 2008). A functional link between NAD+ 
consumption and NAD synthesis here is indicated by the observation that NMNAT2 
expression levels and activity might be associated with malignancy of cancer cells (Sorci et 
al., 2007). In this regard, it was intriguing to discover the activating effect of the cancer-
preventive green tea polyphenol (-)-epigallocatechin 3-gallate (EGCG) on particularly 
NMNAT2 activity. EGCG is an effective scavenger of reactive oxygen species (ROS) that 
induces apoptosis in tumour cells but not normal cells (Shankar et al., 2007). It would be 
interesting to see whether some of its effects are related to NMNAT activity. 
 
4.2 The phosphorylation state of NMNAT1 and PARP1 activity 
 In paper III, we could demonstrate a direct impact of an NMNAT1 on cellular DNA 
damage response and oxidative stress induced cell death. This nuclear enzyme accelerates 
PARP1 activation and AIF translocation upon oxidative stress and DNA damage. In contrast 
to the proposed impact of NMNAT1 on SIRT1 function (Araki et al., 2004), we found that the 
stimulation of PARP1 does not require NMNAT activity. This effect is regulated by the 
phosphorylation status of NMNAT1. A negative charge at Ser136 diminishes both the physical 
interaction of NMNAT1 with poly(ADP-ribosyl)ated PARP1 and PARP1 activation. Since 
NMNAT1 is a homo-hexameric enzyme (Garavaglia et al., 2002; Werner et al., 2002; Zhou et 
al., 2002), successive phosphorylation could gradually regulate the degree of PARP1 activity 
and, moreover, represent the decisive switch between AIF mediated apoptosis and 
NAD/energy depletion-induced necrotic cell death. 
 Importantly, Ser136 is target of protein C kinase (PKC), which has been reported to 
directly phosphorylate and, thereby, inhibit PARP1 itself (Hegedus et al., 2008). Nevertheless, 
the PKC isoform which modifies NMNAT1 in vivo has not yet been identified. Therefore, 
NMNAT1 and PARP1 could be targets of different PKC isoforms. Additionally, the 
identification of the protein phosphatase which dephosphorylates NMNAT1 should be of 
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great interest since it would further disclose the regulatory pathway upstream to the NMNAT1 
effect. 
 
4.3 Targeting of human NMNATs is mediated by an isoform-specific domain 
 The phosphorylation site of NMNAT1 resides within a structural loop which as well 
harbours the enzyme’s nuclear localisation signal (Schweiger et al., 2001; Sasaki et al., 2006). 
Its flexibility and location at the outer surface of the homo-hexamer make this region 
accessible for modification and interaction. An extended equivalent in NMNAT2 mediates 
Golgi association and membrane anchoring by post-translational cysteine palmitoylation. 
Conclusively, in paper II, we propose this region to constitute an independent domain 
implicated in isoform-specific targeting and interaction. This is justified by three 
observations. (i), this domain is not part of the conserved active fold. (ii), NMNAT activity is 
not affected upon deletion of this domain. (iii), bacterial NMNATs are lacking this domain. 
Moreover, in the human homologues, we could find that the amino acids spanning this 
domain are encoded by individual exons. This observation implies that the domain could have 
inserted into an ancestral NMNAT for example by exon shuffling (Ponting&Russel, 2002). 
Unravelling the origin of this isoform-specific targeting and interaction domain (ISTID) might 
shed light on both the evolutionary development of NMNATs and the possible occurrence of 
similar regulatory strategies in other protein families. 
 We could demonstrate that human NMNAT isoform 3 is targeted to the mitochondria. 
We, however, did not investigate the role of the enzyme’s ISTID in this process. NMNAT3 
lacks a putative N-terminal targeting signal, most likely due to the immediate occurrence of 
the Rossmann fold’s first β-sheet and the conserved NMNAT-specific active site. If 
mitochondrial localisation of this isoform were indeed facilitated by its ISTID, this would 
represent an alternative mitochondrial import mechanism. 
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4.4 Mitochondrial NAD synthesis 
 NMNAT3 is the only NAD biosynthetic activity which has been associated with the 
mitochondria. With regard to precursor availability this finding seems puzzling, because 
neither pyridine mono- nor dinucleotides are assumed to pass the inner mitochondrial 
membrane under physiological conditions. In addition, specific transporters have not been 
identified in mammals. Thus, the initial precursor of mitochondrial NAD biosynthesis has not 
been found. Interestingly, our results in paper I demonstrated that NMNAT3 exhibits rather 
low substrate selectivity with regard to purine and pyridine nucleotides in both, the forward 
and the reverse reaction. Most strikingly, NMNAT3 readily accepts and converts the reduced 
forms of NMN and NAD in vitro. A possibility to generate NMNH, besides reducing NMN, 
would be the phosphorylation of reduced nicotinamide riboside (NRH) by one of the recently 
discovered NRK activities. Together, this could allow for direct synthesis of NADH in 
mitochondria and, thus, contribute to the low NAD+/NADH ratio in this organelle (Zhang et 
al., 2002). That mitochondrial NMNH may be of physiological relevance is indicated by our 
findings and supported by the observation that NMNH serves as substrate for mitochondrial 
nicotinamide nucleotide transhydrogenase, NNT (Hu et al., 1998). NNT generates NADPH by 
oxidation of NADH and, thereby, plays a fundamental role in thiol redox homeostasis 
(Rydström J., 2006). Moreover, NMNAT3 activity could directly supply reduced pyridine 
nucleotide equivalents to the mitochondrial respiratory chain. 
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